UVS

Reykjavik, Iceland Founded: 1999 • Age: 27 yrs Acquired By deCODE Genetics
Cancer research is conducted via population genomic studies.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About UVS

UVS is a company based in Reykjavik (Iceland) founded in 1999 was acquired by deCODE Genetics in January 2006. UVS operates in a competitive market with competitors including GSK, Nanopore, Avidity Biosciences, PacBio and Sutro Biopharma, among others.

  • Headquarter Reykjavik, Iceland
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    deCODE Genetics

    (Jan 18, 2006)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of UVS

Premium access

Detailed funding history for UVS

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in UVS

UVS has secured backing from 1 investor. Prominent investors backing the company include deCODE Genetics.

All
Investor Description Founded Year Domain Location
Bioinformatics platform for genetic disease analysis is provided.
Locked Locked Locked
Premium access

Investor details for UVS

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by UVS

Investments
Premium access

Investment portfolio details for UVS

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - UVS

Premium access

Detailed financials for UVS

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Uvs Comparisons

UVS Primary company
Description
Cancer research is conducted via population genomic studies.
Location
Reykjavik, Iceland
Founded Year
1999
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for UVS

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of UVS

UVS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Nanopore, Avidity Biosciences, PacBio and Sutro Biopharma, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of pharmaceuticals and vaccines for various therapeutic areas
Locked Locked Locked
Nanopore-based electronic systems for single-molecule analysis are developed.
Locked Locked Locked
Antibody-siRNA complexes are developed for cancer treatment.
Locked Locked Locked
Instrument systems and software for single-molecule real-time sequencing are developed.
Locked Locked Locked
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
Locked Locked Locked
Yeast cells are genetically engineered to produce medicinal products.
Premium access

Detailed competitors of UVS

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Uvs

Premium access

Complete news archive for UVS

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about UVS

UVS was founded in 1999.

UVS is headquartered in Reykjavik, Iceland.

UVS was founded in 1999 in Reykjavik, Iceland, within the biotechnology sector. Population genomic studies are employed to advance cancer research, with high-throughput sequencing methods applied to analyze the Icelandic population for inherited cancer-related genes like BRCA1 and BRCA2. Operations focus on biomarker discovery and support targeted drug development in oncology.

UVS's top competitors include Nanopore, Sutro Biopharma and Synthego.

UVS has 1 investor. Key investors include deCODE Genetics.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available